drugset
drugset / Trial / NCT00546715

A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects

NCT00546715 ↗

Phase 1/2 Completed 95 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of daclatasvir in subjects with chronic hepatitis C infection

Timeline

Start
2007-11
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Daclatasvir Small molecule 0.5 mg Oral
Comparator Daclatasvir Small molecule 1 mg Oral
Comparator Daclatasvir Small molecule 10 mg Oral
Comparator Daclatasvir Small molecule 100 mg Oral
Comparator Daclatasvir Small molecule 200 mg Oral

Indications

chronic hepatitis C virus infection